(MedPage Today) — Overall survival (OS) in BRCA-mutated breast cancer improved significantly with the addition of olaparib (Lynparza) to neoadjuvant chemotherapy despite no improvement in pathologic response, a small prospective study showed…
Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/115570
Author :
Publish date : 2025-05-13 20:31:00
Copyright for syndicated content belongs to the linked Source.
